COMPANY PRODUCT TYPE THERAPEUTIC AREA INDICATION PHASE STUDIES LOCATION PRODUCT
ADM BIOPOLIS Microbiome Analysis Diagnostic Autoimmune & Inflammation
Dermatology
Digestive System
Metabolic / Endocrinology
Women´s health
Various 5RTM Worldwide Microbiome Analysis
Therapeutic area: Autoimmune & Inflammation
Dermatology
Digestive System
Metabolic / Endocrinology
Women´s health
ADmit Therapeutics ADmit Test Biomarkers / Diagnostic Central Nervous System Alzheimer's disease in prodromic stage (Mild Cognitive Impairment) 3CV Spain, Australia ADmit Test
Therapeutic area: Central Nervous System
ADNTRO ADNTRO Pharmacogenetics Biomarkers Others Clinical dosing guidelines for more than 60 drugs - haplotypes analysis 5RTM Worldwide ADNTRO Pharmacogenetics
Therapeutic area: Others
ADNTRO Biomarkers identification Biomarkers Central Nervous System GWAS to identify genetic variants associated with Alzheimer. 1R+D Spain Biomarkers identification
Therapeutic area: Central Nervous System
ADNTRO ADNTRO Clinical Algorithm Others Others Algorithm to detect pathogenic variants for patients that had been already diagnosed (currently working with oncology patients) 5RTM Worldwide ADNTRO Clinical Algorithm
Therapeutic area: Others
ADNTRO ADNTRO kit Others Others Polygenic risk scores (PRSs) for complex diseases. A useful tool to support medical diagnosis and for diseases prevention. 5RTM Worldwide ADNTRO kit
Therapeutic area: Others
Agrenvec Recombinant proteins, COVID-19 antigens Biomarkers / Diagnostic Infections COVID-19 antigens for immunoassay 3CV SPAIN Recombinant proteins, COVID-19 antigens
Therapeutic area: Infections
Altum Sequencing Clonesight Biomarkers / Diagnostic Cancer Lung 2PreV Europe Clonesight
Therapeutic area: Cancer
Altum Sequencing Clonesight Biomarkers / Diagnostic Cancer Follicular Lymphoma 3CV Europe Clonesight
Therapeutic area: Cancer
Altum Sequencing Clonesight Biomarkers / Diagnostic Cancer Acute Myeloid Leukemia(AML) 3CV Europe Clonesight
Therapeutic area: Cancer
AMADIX (Advanced marker discovery) PancreaDix Biomarkers / Diagnostic Cancer Innovative non-invasive blood-based test for early detection of pancreatic cancer and preneoplastic lesions 3CV Spain PancreaDix
Therapeutic area: Cancer
AMADIX (Advanced marker discovery) DiagnoLung Biomarkers / Diagnostic Cancer Innovative non-invasive blood-based test for early detection of lung cancer in high-risk screening population and in patients with indeterminate pulmonary nodules 3CV Spain DiagnoLung
Therapeutic area: Cancer
APTUS Biotech PrediApt Biomarkers / Diagnostic Cancer Aptusbiotech is developing two prognostic applications in response to platinum derivative treatment in lung cancer using MAFG as diagnostic biomarker and based on aptamers 2PreV Spain PrediApt
Therapeutic area: Cancer
APTUS Biotech Apta-Leish Diagnostic Infections Leishmaniasis diagnosis based on aptamers 1R+D Spain Apta-Leish
Therapeutic area: Infections
APTUS Biotech PHITBAC Diagnostic Infections Aptus is developing nanophotonic biosensors for the diagnosis and clinical management of bacterial infections at the point-of-care. We are selecting novel and exclusive aptamers for the detection of specific antibiotics used in clinics 1R+D PHITBAC
Therapeutic area: Infections
APTUS Biotech AptaDetect-HCV Diagnostic Infections Hepatitis C virus (HCV) diagnosis based on aptamers 1R+D Spain AptaDetect-HCV
Therapeutic area: Infections
Araclon Biotech ABtest-IA Biomarkers Central Nervous System Alzheimer�s disease diagnostic service in the early stages. ISO9001 certified. 5RTM Worldwide ABtest-IA
Therapeutic area: Central Nervous System
Araclon Biotech ABtest-MS Biomarkers Central Nervous System Alzheimer�s disease diagnostic service in the early stages by mass spectrometry. ISO9001 certified. 5RTM Worldwide ABtest-MS
Therapeutic area: Central Nervous System
ATRYS HEALTH Home-Care HTA Patient monitoring equipment Others mediciín, valoraciín y seguimiento de pacientes con HTA 5RTM Home-Care HTA
Therapeutic area: Others
ATRYS HEALTH Personalized Medicine Patient monitoring equipment Cancer Expert system for breast and colon cancer patient management 3CV Spain Personalized Medicine
Therapeutic area: Cancer
ATRYS HEALTH radioproliq Biomarkers Cancer Firma molecular en biopsia léquida para respuesta a radioterapia y recaéda temprana en cáncer de prístata 2PreV radioproliq
Therapeutic area: Cancer
ATRYS HEALTH home care Diabetes Patient monitoring equipment Metabolic / Endocrinology diabetes 5RTM home care Diabetes
Therapeutic area: Metabolic / Endocrinology
ATRYS HEALTH Personalized Medicine Biomarkers Cancer Patient stratification in glioma 3CV Spain Personalized Medicine
Therapeutic area: Cancer
ATRYS HEALTH oncliq Biomarkers / Diagnostic Cancer Desarrollo de una plataforma dinámica de detecciín rápida de alteraciones moleculares accionables a partir de biopsias léquidas y sílidas de pacientes oncolígicos 1R+D oncliq
Therapeutic area: Cancer
ATRYS HEALTH Personalized Medicine Biomarkers / Diagnostic Cancer Patient stratification for difuse large b-cell lymphoma therapy 3CV Spain Personalized Medicine
Therapeutic area: Cancer
ATRYS HEALTH inmunoterapia Biomarkers Cancer Caracterizaciín inmunolígica y molecular en biopsia léquida de pacientes de cáncer de pulmín para inmunoterapia 1R+D inmunoterapia
Therapeutic area: Cancer
ATRYS HEALTH mAb for diagnosis and prognosis of brain tumors and lesions Biomarkers / Diagnostic Cancer
Central Nervous System
Glioblastoma, neurodegenerative disease 1R+D Spain mAb for diagnosis and prognosis of brain tumors and lesions
Therapeutic area: Cancer
Central Nervous System
ATRYS HEALTH telecardio Diagnostic/Imaging Cardiovascular and circulatory systems Herramientas de Telemedicina para la Detecciín y Prevenciín de Enfermedades Cardiovasculares 2PreV telecardio
Therapeutic area: Cardiovascular and circulatory systems
ATRYS HEALTH surveprost Biomarkers Cancer Desarrollo de firma multiímica para predicciín de la agresividad tumoral a partir de biopsia léquida en pacientes de cáncer de prístata. 1R+D colombia surveprost
Therapeutic area: Cancer
ATRYS HEALTH análisis de imágenes mádicas Diagnostic/Imaging Others Inteligencia artificial para el análisis de diferentes imágenes mádicas: mamograféas, radiograféas de torax y radiograféas osteo-articulares 2PreV España, Colombia, Peró análisis de imágenes mádicas
Therapeutic area: Others
Biocross e4Risk Quantitative Biomarkers / Diagnostic Central Nervous System Determination of ApoE4 plasma quantification as a reliable predictor of pathological concentrations of Abeta peptide, Tau and phosphotau in cerebrospinal fluid of patients with clinical suspiction of Alzheimer�s Disease. 2PreV e4Risk Quantitative
Therapeutic area: Central Nervous System
Biocross Degenerative Dementia test Biomarkers / Diagnostic Central Nervous System The Degenerative Dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a �screening� tool for use i 2PreV Europe Degenerative Dementia test
Therapeutic area: Central Nervous System
Biocross e4Risk Biomarkers / Diagnostic Central Nervous System e4Risk is a non-genetic, cost effective, and highly reliable test to evaluate the risk to develop late onset Alzheimer�s Disease. The test detects the presence of the ApoE4 protein in human blood plasma using high-throughput chemical chemistry analyzer. 5RTM Europe e4Risk
Therapeutic area: Central Nervous System
Biocross AD Dementia test Biomarkers / Diagnostic Central Nervous System The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patien 2PreV Europe AD Dementia test
Therapeutic area: Central Nervous System
BIOHOPE Janus kinase (JAK) Inhibitors IMMUNOBIOGRAM Biomarkers / Diagnostic Autoimmune & Inflammation IVD under development with potential application to different immune and inflammatory diseases. It allows to determine the patient's response to Janus kinase (JAK) Inhibitors drugs. 2PreV Spain Janus kinase (JAK) Inhibitors IMMUNOBIOGRAM
Therapeutic area: Autoimmune & Inflammation
BIOHOPE MTX-cell ARTHRITIS Biomarkers / Diagnostic Autoimmune & Inflammation IVD in clinical validation stage that will help to define the best immunosuppressant combination possible for the selection of first line treatment in a certain patient suffering rheumatoid arthritis. 3CV Spain MTX-cell ARTHRITIS
Therapeutic area: Autoimmune & Inflammation
BIOHOPE Transplant IMMUNOBIOGRAM Biomarkers / Diagnostic Kidney and Genitourinary system
Musculoskeletal Disorders
CE marked IVD test that allow the doctor to select the most adequate immunosuppressive regimen for each patient. Market launch under a commercial agreement with Palex Medical. 5RTM Spain, Denmark, Germany, Poland, USA Transplant IMMUNOBIOGRAM
Therapeutic area: Kidney and Genitourinary system
Musculoskeletal Disorders
BIOLAN HEALTH BIOLAN HEALTH COVID-19 Antigen Rapid Test-Self Test Diagnostic Infections The BIOLAN HEALTH COVID-19 Antigen Rapid Test-Self Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleoclapsid antigen of SARS-CoV-2 virus in nasal swab specimens in only 15-20 minutes, for self-diagnosis 5RTM Spain BIOLAN HEALTH COVID-19 Antigen Rapid Test-Self Test
Therapeutic area: Infections
BIOLAN HEALTH BIOLAN HEALTH COVID-19 Antigen Rapid Test Diagnostic Infections The BIOLAN HEALTH COVID-19 Antigen Rapid Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleoclapsid antigen of SARS-CoV-2 virus in nasal swab specimens in only 15-20 minutes, for professional use. 5RTM Spain BIOLAN HEALTH COVID-19 Antigen Rapid Test
Therapeutic area: Infections
BIOLAN HEALTH BIOLAN HEALTH Serological Rapid Test, COVID-19 IgG/IgM Diagnostic Infections Serological Test COVID-19 IgG / IgM Rapid Test Cassette allows to quickly, easily and accurately detect antibodies against SARS-CoV-2 in people who are or have been infected by the virus that causes COVID-19. 5RTM Spain BIOLAN HEALTH Serological Rapid Test, COVID-19 IgG/IgM
Therapeutic area: Infections
BIOLAN HEALTH OSAXYL 7000: for lactose intolerance diagnosis Diagnostic Digestive System The OSAXYL measurement system is a portable tool that allows accurate and reliable diagnosis of hypolactasia (lactose intolerance) by detecting xylose in urine. 5RTM Spain OSAXYL 7000: for lactose intolerance diagnosis
Therapeutic area: Digestive System
Biotechnology Assets CLICK-DIAGNOSTIC Diagnostic Others Splittera technology enhances the sensibility and accuracy of diagnostic systems. Already licensed in non-exclusivity for IVD systems to Biokit 5RTM CLICK-DIAGNOSTIC
Therapeutic area: Others
CIBER New predictive method for the progression of colorectal cancer Biomarkers Cancer It has been patented a new fetal 'gene signature’ capable to predict the worse evolution of the CRC patients who could suffer a relapse after chemotherapeutic regime or surgery. 2PreV Spain New predictive method for the progression of colorectal cancer
Therapeutic area: Cancer
CIBER Haptens, antibodies and method to detect pseudomonas aeruginosa infections Diagnostic Infections Pseudomonas aeruginosa 1R+D Spain Haptens, antibodies and method to detect pseudomonas aeruginosa infections
Therapeutic area: Infections
CIBER SARS-CoV-2 immunogenic polypeptide, anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments Others Infections
Respiratory and Pulmonary system
SARS-COV-2 2PreV SARS-CoV-2 immunogenic polypeptide, anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
Therapeutic area: Infections
Respiratory and Pulmonary system
CIBER Biomarkers and method to predict or predict response to treatment with BRAF and MEK inhibitors (BRAFi + MEKi) and for patient follow-up Biomarkers / Diagnostic Cancer Genetic biomarkers, Cancer 1R+D Biomarkers and method to predict or predict response to treatment with BRAF and MEK inhibitors (BRAFi + MEKi) and for patient follow-up
Therapeutic area: Cancer
CIBER PredictivModel to predict the development of type 2 diabetes mellitus using miRNAs Biomarkers / Diagnostic Metabolic / Endocrinology Type 2 diabetes mellitus (T2DM) 1R+D PredictivModel to predict the development of type 2 diabetes mellitus using miRNAs
Therapeutic area: Metabolic / Endocrinology
CIBER INFORMATIVE BIOMARKERS OF PORTAL HYPERTENSION Biomarkers / Diagnostic Blood and Lymphatic systems Non-invasive method to identify patients suffering from portal hypertension based on the detection of two biomarkers. This one, provides robustness and precision for identifying patients suffering from PH and stratifying those that have CSPH. 1R+D Spain INFORMATIVE BIOMARKERS OF PORTAL HYPERTENSION
Therapeutic area: Blood and Lymphatic systems
CIBER USE OF AN MNK kinase inhibitor for the treatment of Triple-negative breast cancer Biomarkers / Diagnostic Cancer
Women´s health
breast cancer 1R+D USE OF AN MNK kinase inhibitor for the treatment of Triple-negative breast cancer
Therapeutic area: Cancer
Women´s health
CIBER SALIVA-BASED DIAGNOSTIC TEST FOR EOSINOPHILIC OESOPHAGITIS Biomarkers Digestive System This invention provides a method to analyse the diagnosis and/or prognosis of Eosinophilic Oesophagitis (EoE), using determination and quantification of certain salivary biomarkers. 1R+D Spain SALIVA-BASED DIAGNOSTIC TEST FOR EOSINOPHILIC OESOPHAGITIS
Therapeutic area: Digestive System
CIBER BIOMARKERS AND DIAGNOSTIC METHOD FOR MODY NHF1A Biomarkers / Diagnostic Metabolic / Endocrinology New method for the diagnosis and prognosis of the Maturity Onset Diabetes of the Young carrying deleterious HNF1A alleles (MODY HNF1A) by using biomarkers based on microRNAs(miRNAs) and ultrasensitive C-reactive protein (PCR-hs). 1R+D Spain BIOMARKERS AND DIAGNOSTIC METHOD FOR MODY NHF1A
Therapeutic area: Metabolic / Endocrinology
CIBER ALZHEIMER'S DISEASE DIAGNOSTIC BIOMARKER, A METHOD AND KIT BASED ON THE SAME Biomarkers / Diagnostic Central Nervous System It is an in vitro method for the diagnosis of Alzheimer's disease in which the glycosylation pattern of sAPPα and / or sAPPβ in a biological sample is determined. 1R+D Spain ALZHEIMER'S DISEASE DIAGNOSTIC BIOMARKER, A METHOD AND KIT BASED ON THE SAME
Therapeutic area: Central Nervous System
CIBER Methods for the measurement of protein C and activated protein C Biomarkers / Diagnostic Autoimmune & Inflammation
Infections
Sepsis or septic shock 2PreV Spain Methods for the measurement of protein C and activated protein C
Therapeutic area: Autoimmune & Inflammation
Infections
CIBER NON-INVASIVE METHOD FOR COLORECTAL CANCER DETECTION Biomarkers Cancer A new non-invasive method (so called miRFec) with better performance for identifying patients with colorectal cancer (CRC) and advanced adenomas (AA). 1R+D Spain NON-INVASIVE METHOD FOR COLORECTAL CANCER DETECTION
Therapeutic area: Cancer
CIBER Epigenetic biomarkers for the diagnosis and prevention of the evolution of obesity Biomarkers / Diagnostic Metabolic / Endocrinology IBIMA, SAS, University of Málaga and Consorcio Centro de Investigación Biomédica en Red (CIBER) has developed a new methodology useful in the diagnosis and prevention of the evolution of obesity. 1R+D Spain Epigenetic biomarkers for the diagnosis and prevention of the evolution of obesity
Therapeutic area: Metabolic / Endocrinology
CIBER Method for rapid detection of Candida auris and diagnosis of infection caused by this pathogen Diagnostic Infections Candida auris 2PreV Spain Method for rapid detection of Candida auris and diagnosis of infection caused by this pathogen
Therapeutic area: Infections
CIBER ceRNA profile to predict response to immunotherapy in cancer patients Diagnostic Cancer Cancer 2PreV ceRNA profile to predict response to immunotherapy in cancer patients
Therapeutic area: Cancer
CIBER BIOSIGNATURES FOR ULCERATIVE COLITIS Biomarkers Digestive System Biosignature to manage the non-responder corticosteroids patients with personalized approach. 1R+D Spain BIOSIGNATURES FOR ULCERATIVE COLITIS
Therapeutic area: Digestive System
CIBER SEPARATION-OF-FUNCTION I KAPPA B ALPHA MUTANTS Biomarkers / Diagnostic Cancer Cancer 2PreV SEPARATION-OF-FUNCTION I KAPPA B ALPHA MUTANTS
Therapeutic area: Cancer
CIBER METHOD FOR MONITORING OR PREDICTING WHETHER A PATIENT SUFFERING FROM OBESITY IS RESPONDING OR WILL RESPOND TO A VERY-LOW-CALORIE KETOGENIC DIET (VLCKD) Biomarkers / Diagnostic Metabolic / Endocrinology Obesity 2PreV METHOD FOR MONITORING OR PREDICTING WHETHER A PATIENT SUFFERING FROM OBESITY IS RESPONDING OR WILL RESPOND TO A VERY-LOW-CALORIE KETOGENIC DIET (VLCKD)
Therapeutic area: Metabolic / Endocrinology
CIBER BIOMARKERS TO PREDICT LUNG OVERSTRETCHING Biomarkers / Diagnostic Respiratory and Pulmonary system Biomarkers to predict Lung damage 3CV BIOMARKERS TO PREDICT LUNG OVERSTRETCHING
Therapeutic area: Respiratory and Pulmonary system
CIBER IDENTIFICATION OF METABOLOMIC SIGNATURES IN URINE SAMPLES FOR TUBERCULOSIS DIAGNOSIS Biomarkers / Diagnostic Infections
Others
diagnosis of tuberculosis 2PreV IDENTIFICATION OF METABOLOMIC SIGNATURES IN URINE SAMPLES FOR TUBERCULOSIS DIAGNOSIS
Therapeutic area: Infections
Others
CIBER PREDICTION OF ACUTE RESPIRATORY DISTRESS IN COVID-19 PATIENTS Diagnostic Respiratory and Pulmonary system SARS-COV-2 2PreV PREDICTION OF ACUTE RESPIRATORY DISTRESS IN COVID-19 PATIENTS
Therapeutic area: Respiratory and Pulmonary system
CIBER METHOD FOR EARLY TAKO-TSUBO CARDIOMIOPHATY PROGNOSIS IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE Diagnostic Respiratory and Pulmonary system ANEURYSMAL SUBARACHNOID HEMORRHAGE 2PreV METHOD FOR EARLY TAKO-TSUBO CARDIOMIOPHATY PROGNOSIS IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE
Therapeutic area: Respiratory and Pulmonary system
CIBER CIRCULATING miRNAS AS BIOMARKERS FOR DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER´S DISEASE Biomarkers / Diagnostic Central Nervous System Our research group is developing a cost-effective molecular kit based on the analysis of a miRNA signature as non-invasive blood-biomarker for early diagnosis of Alzheimer’s disease. 1R+D Spain CIRCULATING miRNAS AS BIOMARKERS FOR DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER´S DISEASE
Therapeutic area: Central Nervous System
CIBER Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques Biomarkers / Diagnostic Central Nervous System In vitro method for diagnosis, prognosis and monitoring of Alzheimer's disease using the metabolic profile in serum of an individual. The method includes a NMR acquisition protocol, a mathematical algorithm and a software for data processing. 1R+D Spain Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques
Therapeutic area: Central Nervous System
CIBER Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques Diagnostic Central Nervous System Alzheimer disease 2PreV Spain Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques
Therapeutic area: Central Nervous System
CIBER METHOD FOR PREDICTING MORTALITY IN COVID-19 PATIENTS Diagnostic Respiratory and Pulmonary system SARS-CoV-2 2PreV METHOD FOR PREDICTING MORTALITY IN COVID-19 PATIENTS
Therapeutic area: Respiratory and Pulmonary system
DIOMUNE SL SEPSISpredict Biomarkers / Diagnostic Cardiovascular and circulatory systems
Infections
Heart Infarction 2PreV Spain SEPSISpredict
Therapeutic area: Cardiovascular and circulatory systems
Infections
FERRER EPICUP (FAB-115) Diagnostic Cancer Cancer of Unkown Primary 5RTM Europe EPICUP (FAB-115)
Therapeutic area: Cancer
FERRER EPIBREAST (FAB-118) Diagnostic Cancer Breast Cancer 1R+D Europe EPIBREAST (FAB-118)
Therapeutic area: Cancer
FLOMICS BIOTECH Flomics liquid biopsy Biomarkers / Diagnostic Cancer Liquid biopsy for the early detection of multiple types of cancer 2PreV Spain Flomics liquid biopsy
Therapeutic area: Cancer
FLOMICS BIOTECH Flomics CA liquid biopsy Biomarkers / Diagnostic Central Nervous System Liquid biopsy for the early detection of Cerebellar Atrophy 2PreV Flomics CA liquid biopsy
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD FISEVI-19002 MedicalForms: Clinical Information Modeling Tool Others Others Clinical Information Modeling Tool 1R+D FISEVI-19002 MedicalForms: Clinical Information Modeling Tool
Therapeutic area: Others
FUND. PROGRESO Y SALUD GENYO-19002 METHOD OF OBTAINING USEFUL DATA TO DIAGNOSE HEREDITARY HEMORRHAGIC TELANGIECTASIA Diagnostic Cardiovascular and circulatory systems Method of obtaining useful data to diagnose hereditary hemorrhagic telangiectasia. 1R+D GENYO-19002 METHOD OF OBTAINING USEFUL DATA TO DIAGNOSE HEREDITARY HEMORRHAGIC TELANGIECTASIA
Therapeutic area: Cardiovascular and circulatory systems
FUND. PROGRESO Y SALUD FIBAO-19010, Biomarkers for non-invasive diagnosis of pancreatic ductal adenocarcinoma Biomarkers / Diagnostic Cancer Pancreatic ductal adenocarcinoma 2PreV SPAIN FIBAO-19010, Biomarkers for non-invasive diagnosis of pancreatic ductal adenocarcinoma
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FIBAO-19006 y 09 Gene therapy with hokD and ldrB genes for cancer treatment Others Cancer Gene Therapy - Cancer 2PreV SPAIN FIBAO-19006 y 09 Gene therapy with hokD and ldrB genes for cancer treatment
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FIMABIS-20015 HemoPer: APP for the management of antithrombotics in perioperative, emergency and COVID19 context Others Others APP for the management of antithrombotics in perioperative, emergency and COVID19 context 1R+D FIMABIS-20015 HemoPer: APP for the management of antithrombotics in perioperative, emergency and COVID19 context
Therapeutic area: Others
FUND. PROGRESO Y SALUD FIMABIS-21005 CUIDAVEN Others Others App for the Care of Venous Devices 1R+D FIMABIS-21005 CUIDAVEN
Therapeutic area: Others
FUND. PROGRESO Y SALUD FIMABIS-20034 Lactoperoxidase as a potential diagnostic method for the presence of Parkinson's disease and response to treatment Diagnostic Central Nervous System Parkinson, Lactoperoxidase as a potential diagnostic method for the presence of Parkinson's disease and response to treatment 1R+D FIMABIS-20034 Lactoperoxidase as a potential diagnostic method for the presence of Parkinson's disease and response to treatment
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD FISEVI-15004 Portable vest for the application of pulmonary therapy and associated procedure Others Others Portable vest for the application of pulmonary therapy and associated procedure 1R+D FISEVI-15004 Portable vest for the application of pulmonary therapy and associated procedure
Therapeutic area: Others
FUND. PROGRESO Y SALUD GENYO-20003 SYSTEM FOR THE SIMULTANEOUS DETECTION OF CHROMOSOME ALTERATIONS THROUGH SEQUENCING, CYTOMETRY AND IMAGE. Diagnostic Others SYSTEM FOR THE SIMULTANEOUS DETECTION OF CHROMOSOME ALTERATIONS THROUGH SEQUENCING, CYTOMETRY AND IMAGE. 1R+D GENYO-20003 SYSTEM FOR THE SIMULTANEOUS DETECTION OF CHROMOSOME ALTERATIONS THROUGH SEQUENCING, CYTOMETRY AND IMAGE.
Therapeutic area: Others
FUND. PROGRESO Y SALUD FISEVI-20011 FEN-COVID-19 Diagnostic Others Covid-19 1R+D FISEVI-20011 FEN-COVID-19
Therapeutic area: Others
FUND. PROGRESO Y SALUD GENYO-21001 MyPROSLE: a new system to measure the personalized molecular dysregulated profiles of Systemic Lupus Erythematosus patients Diagnostic Autoimmune & Inflammation MyPROSLE: a new system to measure the personalized molecular dysregulated profiles of Systemic Lupus Erythematosus patients 1R+D GENYO-21001 MyPROSLE: a new system to measure the personalized molecular dysregulated profiles of Systemic Lupus Erythematosus patients
Therapeutic area: Autoimmune & Inflammation
FUND. PROGRESO Y SALUD FIBICO-19012 Use of splicing factors as therapeutic targets in prostate cancer. Diagnostic Cancer Use of splicing factors as therapeutic targets in prostate cancer. 1R+D FIBICO-19012 Use of splicing factors as therapeutic targets in prostate cancer.
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FIMABIS-20015 HemoPer: APP for the management of antithrombotics in perioperative, emergency and COVID19 context Others Others Covid-19 1R+D FIMABIS-20015 HemoPer: APP for the management of antithrombotics in perioperative, emergency and COVID19 context
Therapeutic area: Others
FUND. PROGRESO Y SALUD FIMABIS-14005 Breast cancer biomarkers Biomarkers Cancer Breast cancer 2PreV FIMABIS-14005 Breast cancer biomarkers
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FISEVI-18026 CellCount-Master Others SYSTEM AND METHOD OF QUANTIFICATION AND CHARACTERIZATION OF CLUSTERS ASSOCIATED WITH CIRCULATING TUMOR CELLS (CTCs) 1R+D FISEVI-18026 CellCount-Master
Therapeutic area:
FUND. PROGRESO Y SALUD FISEVI-15028 Mobile application for the monitoring and diagnosis of surgical wound infections on an outpatient basis using an image-based telemedicine system (Scarcheck) Diagnostic Mobile application for the monitoring and diagnosis of surgical wound infections on an outpatient basis using an image-based telemedicine system (Scarcheck) 1R+D FISEVI-15028 Mobile application for the monitoring and diagnosis of surgical wound infections on an outpatient basis using an image-based telemedicine system (Scarcheck)
Therapeutic area:
FUND. PROGRESO Y SALUD FISEVI-20005 Equivalent dose converter between different drugs Others Others Equivalent dose converter between different drugs 1R+D FISEVI-20005 Equivalent dose converter between different drugs
Therapeutic area: Others
FUND. PROGRESO Y SALUD FIMABIS-21007 Predict plus Prevent Others Substance Abuse Mental Health, Predict plus Prevent is a set of calculators to predict the appearance of future episodes of depression, anxiety and / or problems with alcohol 1R+D FIMABIS-21007 Predict plus Prevent
Therapeutic area: Substance Abuse
FUND. PROGRESO Y SALUD GENYO-13001 / FIMABIS-13009 Biomarkers Autoimmune & Inflammation Lupus erythematosus / Allergy 2PreV Europe GENYO-13001 / FIMABIS-13009
Therapeutic area: Autoimmune & Inflammation
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) Biomarkers for detecting renal disease Biomarkers / Diagnostic Kidney and Genitourinary system Biomarker for predicting the response of patients suffering from renal disease 1R+D Spain Biomarkers for detecting renal disease
Therapeutic area: Kidney and Genitourinary system
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) GPCRA RECEPTOR AGONIST APTAMERS Diagnostic Others Diagnostic and therapeutic value 1R+D Spain GPCRA RECEPTOR AGONIST APTAMERS
Therapeutic area: Others
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) NEW METHOD FOR IDENTIFYING RISK FACTORS ASSOCIATED TO HYPERTENSION Diagnostic Cardiovascular and circulatory systems
Kidney and Genitourinary system
Method and kit for identifying albuminuria development risk,renal injury risk and cardiovascular risk in a hypertensive human subject 1R+D Spain NEW METHOD FOR IDENTIFYING RISK FACTORS ASSOCIATED TO HYPERTENSION
Therapeutic area: Cardiovascular and circulatory systems
Kidney and Genitourinary system
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) COMPOUNDS FOR USE IN THE TREATMENT AND/OR SEPTICEMIA PREVENTION Diagnostic Infections
Others
The present invention relates to proteins comprising the catalytic domain of a cytotoxic necrotic factor from Yersinia pseudotuberculosis (CNFY), for use in the treatment and/or prevention of septicemia and/or edema associated with sepsis in one subject. 1R+D Spain COMPOUNDS FOR USE IN THE TREATMENT AND/OR SEPTICEMIA PREVENTION
Therapeutic area: Infections
Others
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) Differential biomarkers of severity in asthma Biomarkers Respiratory and Pulmonary system Biomarkers of several clinical phenotypes of asthma 1R+D Spain Differential biomarkers of severity in asthma
Therapeutic area: Respiratory and Pulmonary system
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) SEPT6-ABL2 FUSION FOR USE IN THE DIAGNOSIS AND/OR TREATMENT OF CANCER Diagnostic Others The invention refers to the medical field. Particularly, the present invention refers to a cell linecharacterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2]. 1R+D Spain SEPT6-ABL2 FUSION FOR USE IN THE DIAGNOSIS AND/OR TREATMENT OF CANCER
Therapeutic area: Others
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) IN VIVO LENTIVIRAL GENE THERAPY FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 Others Others Researchers propose the use of LV based on the vector used for the treatment of Haemophilia B for the treatment of primary hyperoxaluria type 1 1R+D Spain IN VIVO LENTIVIRAL GENE THERAPY FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1
Therapeutic area: Others
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) MESENCHYMAL CELLS FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION Others Ophthalmology and optometry The invention relates to a substantially pure population of mesenchymal stem cells for use in the prophylactic and/or therapeutic treatment of Meibomian Gland Dysfunction. 1R+D Spain MESENCHYMAL CELLS FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION
Therapeutic area: Ophthalmology and optometry
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) "BACTERIOPHAGE SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA (1 fago)" Others Others The present invention refers to the medial field. Particularly, the present invention refers to a bacteriophage deposited at the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ) with deposit number DSM34223on 17th of March 2022. In a pref 1R+D Spain "BACTERIOPHAGE SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA (1 fago)"
Therapeutic area: Others
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) "BACTERIOPHAGES SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY KLEBSIELLA PNEUMONIAE (6 fagos)" Others Others The present invention refers to a bacteriophage deposited at the German Collection of Microorganisms and Cell Cultures GmbH (Leibniz Institute) (DSMZ)with deposit number DSM34222, and to a bacteriophage characterized by comprising a nucleic acid consist 1R+D Spain "BACTERIOPHAGES SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY KLEBSIELLA PNEUMONIAE (6 fagos)"
Therapeutic area: Others
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) "BACTERIOPHAGE SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY MYCOBACTERIUM ABSCESSUS (3 fagos)" Others Others The present invention refers to a bacteriophage deposited at the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ) with deposit number DSM 34221, or a bacteriophage comprising a nucleic acid having at least 95% of identity with the nucleic 1R+D "BACTERIOPHAGE SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY MYCOBACTERIUM ABSCESSUS (3 fagos)"
Therapeutic area: Others
Fundacion MEDINA In vitro tests for toxicity, safety, ADME and plasma efficacy Diagnostic/Imaging Others Cytotoxicity, Neurotoxicity, Mitochondrial Toxicity, Cardiotoxicity, ADME tox 5RTM Spain In vitro tests for toxicity, safety, ADME and plasma efficacy
Therapeutic area: Others
Fundacion MEDINA Biomarkers Platform Biomarkers / Diagnostic Cancer Lung Colon Breast Pancreas 3CV Spain Biomarkers Platform
Therapeutic area: Cancer
Fundacion MEDINA Metabolomics Biomarkers Identification Platform Biomarkers / Diagnostic Cancer
Infections
Metabolic / Endocrinology
Cancer Infectious Metabolism and Infectious Biomarkers 3CV Spain Metabolomics Biomarkers Identification Platform
Therapeutic area: Cancer
Infections
Metabolic / Endocrinology
IIS La Fe Biomarkers predictive of cardiac ischemia risk Biomarkers / Diagnostic Cardiovascular and circulatory systems Circulating miRNAs whose altered levels in serum/plasma of patients may be related to the risk of suffering anischaemic event. 2PreV Spain Biomarkers predictive of cardiac ischemia risk
Therapeutic area: Cardiovascular and circulatory systems
IIS La Fe miRNA based Diagnostic method for bladder cancer Biomarkers / Diagnostic Cancer miRNA profiling basen in cuantification of 7 miRNAs for the detection and stratification of patients suffering from bladder cancer 2PreV Spain miRNA based Diagnostic method for bladder cancer
Therapeutic area: Cancer
IIS La Fe Method for predicting response to continuous positive air pressure treatment Diagnostic Respiratory and Pulmonary system Predictive method of response to treatment with continuous positive air pressure (CPAP) in patients with sleep apnea and resistant hypertension. 1R+D Spain Method for predicting response to continuous positive air pressure treatment
Therapeutic area: Respiratory and Pulmonary system
IIS La Fe Determination of autoantibodies in autoimmune patients Ro/SSA+ Biomarkers / Diagnostic Autoimmune & Inflammation Measurement in a piezoelectric resonator of the relationship between different variables of an interfacial process of molecular recognition antigen-antibody for the screening of samples of autoimmune patients. 1R+D Spain Determination of autoantibodies in autoimmune patients Ro/SSA+
Therapeutic area: Autoimmune & Inflammation
IIS La Fe Composition comprising oxylipins present in human milk derived small extracellular vesicles and its use in the prevention and treatment of intestinal diseases Biomarkers / Diagnostic Digestive System Breast milk derived Evs as a combination of pro-resolutive oxilipines (14-HDHA, 17-HDHA, 19,20-DiHDPA). Potential beneficial effects for prevent intestinal disfunction and achieving digestive system maturity. 1R+D Spain Composition comprising oxylipins present in human milk derived small extracellular vesicles and its use in the prevention and treatment of intestinal diseases
Therapeutic area: Digestive System
IIS La Fe Method for predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy Biomarkers / Diagnostic Cancer
Cardiovascular and circulatory systems
In vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy 5 based on the determination of the expression levels of a combination of 10 circulating miRNAs 2PreV Method for predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy
Therapeutic area: Cancer
Cardiovascular and circulatory systems
IMMUNOSTEP Disposable device for leukocyte separation Diagnostic Autoimmune & Inflammation
Blood and Lymphatic systems
Hematological malignancies 2PreV Spain Disposable device for leukocyte separation
Therapeutic area: Autoimmune & Inflammation
Blood and Lymphatic systems
IMMUNOSTEP Infiltration in CNS Diagnostic Cancer Detection of Leptomeningeal disease 4Reg. Worldwide Infiltration in CNS
Therapeutic area: Cancer
IMMUNOSTEP Anti-SARS-CoV-2 Test Multiantégeno para IgG+IgA+IgM Diagnostic/Imaging Infections Multiantigen IgG+IgA+IgM Assay is a multiplex, microsphere-based, highly sensitive and specific assay that measure the presence or absence of antibodies against four different SARS-CoV-2 antigens simultaneously. 4Reg. EUROPA Anti-SARS-CoV-2 Test Multiantégeno para IgG+IgA+IgM
Therapeutic area: Infections
IMMUNOSTEP Hemodiluciín (Bmplex) Diagnostic Blood and Lymphatic systems Detection of hemodilution in bone marrow samples 3CV Worldwide Hemodiluciín (Bmplex)
Therapeutic area: Blood and Lymphatic systems
IMMUNOSTEP ThromboStep Diagnostic Cardiovascular and circulatory systems Autoimmune Thrombocytopenia Diagnosis by flow cytometry 5RTM Europe ThromboStep
Therapeutic area: Cardiovascular and circulatory systems
Ingenasa / Gold Standard Diagnostics Madrid INgezim® COVID RBD-DR Diagnostic Infections ELISA for Antibody detection of COVID 19 at Human and animals. 3CV INgezim® COVID RBD-DR
Therapeutic area: Infections
IRYCIS New aptamers for diagnosis of COVID19 Biomarkers / Diagnostic Autoimmune & Inflammation
Others
Development of therapeutic aptamers against the SARS-Cov2 spike protein and different highly conserved viral peptides in regions involved in the entry of the virus 1R+D New aptamers for diagnosis of COVID19
Therapeutic area: Autoimmune & Inflammation
Others
IRYCIS New aptamers against HCV Biomarkers / Diagnostic Infections C hepatitis 2PreV New aptamers against HCV
Therapeutic area: Infections
IRYCIS New biomarkers to identify good responders to cis-platinum in lug cancer Biomarkers / Diagnostic Cancer New biomarkers based on aptamers technology (target MAFG) to identify good responders to cis-platinum in lug cancer 2PreV New biomarkers to identify good responders to cis-platinum in lug cancer
Therapeutic area: Cancer
IRYCIS Aptamers against MNK1 for the treatment of breast cancer Others Cancer Aptamers against MNK1 for the treatment of breast cancer 2PreV Aptamers against MNK1 for the treatment of breast cancer
Therapeutic area: Cancer
IRYCIS Diagnosis of melanoma with support of AI Diagnostic Dermatology Artificial intelligence in dermatology 5RTM Diagnosis of melanoma with support of AI
Therapeutic area: Dermatology
IRYCIS Diagnosis of osteoporosis with support of AI Diagnostic Musculoskeletal Disorders
Others
Osteoporosis 1R+D Diagnosis of osteoporosis with support of AI
Therapeutic area: Musculoskeletal Disorders
Others
IRYCIS Predictive biomarkers of response after neoadjuvant therapy in locally advanced rectal adenocarcinoma Biomarkers Cancer rectal adenocarcinoma 1R+D Predictive biomarkers of response after neoadjuvant therapy in locally advanced rectal adenocarcinoma
Therapeutic area: Cancer
IRYCIS New biomarkers to predict secundary autoimmunity before the treatment with alemtuzumab in MS Biomarkers Autoimmune & Inflammation
Central Nervous System
New method to determine the probability to develop a secondary autoimmune disease before the treatment with alemtuzumab in patients with Multiple Sclerosis 5RTM Spain New biomarkers to predict secundary autoimmunity before the treatment with alemtuzumab in MS
Therapeutic area: Autoimmune & Inflammation
Central Nervous System
IRYCIS miRNA 127 agents for use in the treatment of renal fibrosis Biomarkers / Diagnostic Kidney and Genitourinary system A method of prophylactically or therapeutically treating Chronic kidney disease (CKD) or of reducing the risk of CKD disease progression in a patient comprising expressing miR-127 in the renal cells 3CV Spain miRNA 127 agents for use in the treatment of renal fibrosis
Therapeutic area: Kidney and Genitourinary system
IRYCIS Biomarkers to identify the response to OIT of children allergics to caw milk proteins Biomarkers / Diagnostic Autoimmune & Inflammation
Others
Biomarkers based on IgE profile for determining oral immunotherapy treatment response in children with cow’s milk protein allergy (with F. Hospital CI) 3CV Spain Biomarkers to identify the response to OIT of children allergics to caw milk proteins
Therapeutic area: Autoimmune & Inflammation
Others
IRYCIS Noverl biomarkers of acute kidney injury based on miRNAs Biomarkers / Diagnostic Kidney and Genitourinary system The identified panel of miRNAs can detect acute kidney injury (AKI) development before serum creatinine increases 3CV Spain Noverl biomarkers of acute kidney injury based on miRNAs
Therapeutic area: Kidney and Genitourinary system
IRYCIS Biomarkers to identify IFN-BETA drug responders in patients with multiple sclerosis Biomarkers / Diagnostic Autoimmune & Inflammation
Central Nervous System
New patented method to identify good responders to Interferon beta (INF-beta) therapy in multiple sclerosis before treatment initiation 5RTM Spain Biomarkers to identify IFN-BETA drug responders in patients with multiple sclerosis
Therapeutic area: Autoimmune & Inflammation
Central Nervous System
IRYCIS Biomarkers to identify ocrelizumab good drug responders in patients with PP multiple sclerosis Biomarkers Autoimmune & Inflammation
Central Nervous System
Primary progressive multiple sclerosis 3CV Biomarkers to identify ocrelizumab good drug responders in patients with PP multiple sclerosis
Therapeutic area: Autoimmune & Inflammation
Central Nervous System
Leitat COVID Diagnostic Infections Antibodies with several tags and different formats for diagnostic use in COVID 2PreV COVID
Therapeutic area: Infections
Leitat ELISA kit to detect biomarker levels (S100A7) Biomarkers / Diagnostic Autoimmune & Inflammation
Cancer
Diagnosis and prognosis of several cancers 2PreV Spain ELISA kit to detect biomarker levels (S100A7)
Therapeutic area: Autoimmune & Inflammation
Cancer
Leitat ELISA kit to detect biomarker levels (S100P) Biomarkers / Diagnostic Autoimmune & Inflammation
Cancer
Diagnosis and prognosis of Pancreatic cancer, colon cancer, others 2PreV Spain ELISA kit to detect biomarker levels (S100P)
Therapeutic area: Autoimmune & Inflammation
Cancer
Leitat ELISA kit to detect biomarker levels (S100A4) Biomarkers / Diagnostic Autoimmune & Inflammation
Cancer
Diagnosis and prognosis of Pancreatic cancer, colon cancer, others 2PreV Spain ELISA kit to detect biomarker levels (S100A4)
Therapeutic area: Autoimmune & Inflammation
Cancer
Leitat Tailored-made formulations with nanoencapsulated active compounds Others Autoimmune & Inflammation
Dermatology
Atopic dermatitis, psoriasis 1R+D Spain Tailored-made formulations with nanoencapsulated active compounds
Therapeutic area: Autoimmune & Inflammation
Dermatology
Leitat Microbiome profile Biomarkers Cancer
Dental
Dermatology
Digestive System
Metabolic / Endocrinology
microbiome characterization (including 3 biomes: bacteria, fungi and viruses) and its relantionship with health&disease, response to treatments 2PreV Microbiome profile
Therapeutic area: Cancer
Dental
Dermatology
Digestive System
Metabolic / Endocrinology
Leitat Metabolic profile Biomarkers Infections Helicobacter pylori infection, oxidative stress 1R+D Spain Metabolic profile
Therapeutic area: Infections
Leitat In vitro cellular model for diagnosis Biomarkers Infections Helicobacter pylori virulence 1R+D Spain In vitro cellular model for diagnosis
Therapeutic area: Infections
Leitat Ready-to-use transport kits for xenobiotic interaction studies Others Others To identify xenobiotic interactions for regulatory purposes 5RTM Europe Ready-to-use transport kits for xenobiotic interaction studies
Therapeutic area: Others
Life Length Telomere Analysis Technology (TAT Test) Biomarkers Cancer
Cardiovascular and circulatory systems
Others
Age related diseases, Cancer, Cardiovascular, Degenerative diseases 5RTM Europe, US Telomere Analysis Technology (TAT Test)
Therapeutic area: Cancer
Cardiovascular and circulatory systems
Others
Merck / Sysmex Inostics Liquid Biopsy RAS Biomarker Testing Biomarkers / Diagnostic Cancer
Digestive System
Metastatic colorectal cancer 1R+D Spain Liquid Biopsy RAS Biomarker Testing
Therapeutic area: Cancer
Digestive System
NIMGENETICS TromboNIM Diagnostic Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Estudio genático de la trombofilia hereditaria dirigido a la identificaciín de pacientes con un riesgo incrementado de desarrollar enfermedad tromboembílica. Analiza 24 variantes en 18 Genes asociadas a un incremento en el riesgo trombítico. Incluye g 5RTM Spain TromboNIM
Therapeutic area: Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
NIMGENETICS ExoNIM Personalizado Diagnostic Genetic Diseases and Dysmorphic syndromes Aproximaciín de ExoNIM® que permite el diseño de un panel de genes adaptados a las necesidades del especialista. Las principales ventajas de esta aproximaciín son: 1. Posibilidad de ampliaciín del análisis por apariciín de nuevos séntomas, redefi 5RTM Spain ExoNIM Personalizado
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
NIMGENETICS KaryoNIM Leukemia Diagnostic Cancer Plataforma genímica diseñada por NIMGenetics para la identificaciín de biomarcadores en la leucemia linfática crínica (LLC), que combina la tecnologéa de array CGH y de SNParray. 1. El array CGH ha demostrado ser la tecnologéa más eficaz en este 5RTM Spain KaryoNIM Leukemia
Therapeutic area: Cancer
NIMGENETICS ExoNIM Plus Epilepsia Diagnostic Genetic Diseases and Dysmorphic syndromes Abordaje global para el estudio de las distintas formas clénicas de la epilepsia que analiza 223 genes con relevancia clénica a partir de la secuenciaciín del exoma completo (ExoNIM®). La secuencia obtenida queda almacenada, lo que permite la aplicaci 5RTM Spain ExoNIM Plus Epilepsia
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
NIMGENETICS ExoNIM Dirigido Diagnostic Genetic Diseases and Dysmorphic syndromes Aproximaciín al análisis del exoma basada en la selecciín de genes asociados al fenotipo del paciente. Tras la secuenciaciín de los 19.000 genes del paciente, se analizan aquellos asociados al cuadro clénico. La secuencia completa queda almacenada, l 5RTM Spain ExoNIM Dirigido
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
NIMGENETICS ExoNIM Trio Diagnostic Genetic Diseases and Dysmorphic syndromes Aproximaciín de ExoNIM® basada en la secuenciaciín de los 19.000 genes del paciente y, sus progenitories. La informaciín genática de los progenitores, permite determinar en las variantes identificadas el patrín de herencia. Esta aproximaciín facilit 5RTM Spain ExoNIM Trio
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
NIMGENETICS ExoNIM Clénico Diagnostic Genetic Diseases and Dysmorphic syndromes Aproximaciín de ExoNIM® que se focaliza en el análisis de genes con fenotipo OMIM (Online Mendelian Inheritance in Man (OMIM). La secuencia completa queda almacenada, lo que permite la realizaciín de diferentes análisis de forma secuencial. ExoNIM® C 5RTM Spain ExoNIM Clénico
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
NIMGENETICS TrisoNIM Excellence Diagnostic Genetic Diseases and Dysmorphic syndromes Test de ADN fetal en sangre materna, mediante secuenciaciín masiva de óltima generaciín (NGS, Next Generation Sequencing) y la aplicaciín del algoritmo NIFTY®. TrisoNIM® es el primer test de ADN fetal realizado éntegramente en España. TrisoNIM® Exc 5RTM Spain TrisoNIM Excellence
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Oniria Therapeutics EpiGold-G Biomarkers / Diagnostic Cancer Detection of epigenetic modifications in liquid biopsies 1R+D EpiGold-G
Therapeutic area: Cancer
OPERON CT/NG/MG Oligogen Diagnostic Infections Molecular test for the simultaneous detection of Chlamydia trachomatis, Nisseria gonorrhoeae, and Mycobacterium genitalis. 5RTM Spain CT/NG/MG Oligogen
Therapeutic area: Infections
OPERON CT Oligogen Biomarkers / Diagnostic Infections Molecular test for the detection of Chlamydia trachomatis 5RTM Spain CT Oligogen
Therapeutic area: Infections
OPERON S. PneumoStrip Diagnostic Respiratory and Pulmonary system Molecular test for the serotyping of Streptococcus pneumoniae 4Reg. Spain S. PneumoStrip
Therapeutic area: Respiratory and Pulmonary system
OPERON MG Oligogen Biomarkers / Diagnostic Infections Test designed for the detection of�Mycoplasma genitalium 5RTM Spain MG Oligogen
Therapeutic area: Infections
OPERON NG Oligogen Biomarkers / Diagnostic Infections Molecular Test for the detection of�Neisseria goorrhoeae 5RTM Spain NG Oligogen
Therapeutic area: Infections
Progenika Biopharma Promonitor QUICK - PoC Others Autoimmune & Inflammation Point of Care Therapeutic drug monitoring 4Reg. Spain Promonitor QUICK - PoC
Therapeutic area: Autoimmune & Inflammation
Progenika Biopharma Promonitor - ELISA Others Autoimmune & Inflammation Therapeutic drug monitoring 5RTM Spain Promonitor - ELISA
Therapeutic area: Autoimmune & Inflammation
PROMEGA BIOTECH IBÉRICA Spectrum Compact CE System Diagnostic Cancer 4-capillary instrument labelled as CE to run MSI fragment analysis for cancer diagnosis 4Reg. Spectrum Compact CE System
Therapeutic area: Cancer
PROMEGA BIOTECH IBÉRICA Lumit SARS-CoV 2 Diagnostic Infections Immunoassay kit to detect SARS-CoV 2 4Reg. Lumit SARS-CoV 2
Therapeutic area: Infections
PROMEGA BIOTECH IBÉRICA Microsatellite Instability Analysis CE-IVD Biomarkers / Diagnostic Cancer Characterize MSI Status by a Fluorescent Multiplex PCR-based method with CE/IVD label 5RTM Global Microsatellite Instability Analysis CE-IVD
Therapeutic area: Cancer
QGENOMICS Quantitative Genomic Medicine Laboratories qGen clinical exome, qGen Trio, qGen Custom 5-10-50-250-500-1000, qGen pathologies Diagnostic Genetic Diseases and Dysmorphic syndromes Clinical exome of >6.000 genes. Trio (adding progenitors), Custom (customized panels), Pathology panels 5RTM Spain qGen clinical exome, qGen Trio, qGen Custom 5-10-50-250-500-1000, qGen pathologies
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories Arrays service: qChip Pre, qChip Post , qChip PdC (60-180-400k-1M) Diagnostic Genetic Diseases and Dysmorphic syndromes Microarrays (60k ISO 15189 certified) 5RTM Spain Arrays service: qChip Pre, qChip Post , qChip PdC (60-180-400k-1M)
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories Custom gene expression Microarray Biomarkers / Diagnostic Genetic Diseases and Dysmorphic syndromes Customized gene expression microarray study 5RTM Spain Custom gene expression Microarray
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories qCancer: BRCA1/2, Mama, Gine, Colorrectal, Risk, Risk Expanded Biomarkers / Diagnostic Cancer NGS panels to detect the level of hereditary Cancer risk 5RTM Spain qCancer: BRCA1/2, Mama, Gine, Colorrectal, Risk, Risk Expanded
Therapeutic area: Cancer
QGENOMICS Quantitative Genomic Medicine Laboratories Arrays kits (60-180k, with SNP) Diagnostic Genetic Diseases and Dysmorphic syndromes Arrays kits to integrate the process in the center 5RTM Spain Arrays kits (60-180k, with SNP)
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories qTranscriptome Others Genetic Diseases and Dysmorphic syndromes mRNA analysis through RNA-Seq (30MR 2x150bp) 5RTM Spain qTranscriptome
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories qGenEx: Research, Trio, Custom, Pathologies Diagnostic Genetic Diseases and Dysmorphic syndromes Whole exome of >20.000 genes. Trio (adding progenitors), Custom (customized panels), Pathology panels. 5RTM Spain qGenEx: Research, Trio, Custom, Pathologies
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories qMicrobiome: endometrial and vaginal Diagnostic Infections
Women´s health
NGS test (V4 and V5 from rRNA 16S) to detect the endometrial and vaginal bacteria, Candida and HPV. 5RTM Spain qMicrobiome: endometrial and vaginal
Therapeutic area: Infections
Women´s health
QGENOMICS Quantitative Genomic Medicine Laboratories Custom qPCR Others Genetic Diseases and Dysmorphic syndromes Customized quantitative PCR 5RTM Spain Custom qPCR
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories qCarrier: Plus, Plus Extended Compatibility, Plus Pareja, Auto, Auto Extended Compatibility, qExpect Others Genetic Diseases and Dysmorphic syndromes NGS Carrier Test for Recessive Diseases 5RTM Spain qCarrier: Plus, Plus Extended Compatibility, Plus Pareja, Auto, Auto Extended Compatibility, qExpect
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories Other molecular tests: MLPA, Sanger, FISH, microsatelites, qCell Identity Diagnostic Genetic Diseases and Dysmorphic syndromes Other molecular tests for validation or specific clinical suspicions 5RTM Spain Other molecular tests: MLPA, Sanger, FISH, microsatelites, qCell Identity
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories CGH arrays ad-hoc Others Genetic Diseases and Dysmorphic syndromes Copy Number determination in specific regions 5RTM Spain CGH arrays ad-hoc
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
QGENOMICS Quantitative Genomic Medicine Laboratories qGenome Others Genetic Diseases and Dysmorphic syndromes Whole genome sequencing (30x coverage), bioinformatic analysis and expert interpretation 5RTM qGenome
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
SECUGEN Service for the detection and quantification of autoantibodies against CFH and CFI Biomarkers Autoimmune & Inflammation
Genetic Diseases and Dysmorphic syndromes
Complement system related disorders 5RTM Spain Service for the detection and quantification of autoantibodies against CFH and CFI
Therapeutic area: Autoimmune & Inflammation
Genetic Diseases and Dysmorphic syndromes
SECUGEN GENOTYPING Diagnostic/Imaging Ophthalmology and optometry Genetic risk for Age related Macular Degeneration 5RTM Worldwide GENOTYPING
Therapeutic area: Ophthalmology and optometry
SECUGEN NEXT GEN SEQUENCING Diagnostic/Imaging Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Kidney and Genitourinary system
Genetic Diagnosis 5RTM Worldwide NEXT GEN SEQUENCING
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Kidney and Genitourinary system
SECUGEN DNA SEQUENCING Diagnostic/Imaging Genetic Diseases and Dysmorphic syndromes Genetic Diagnosis 5RTM Worldwide DNA SEQUENCING
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Vicomtech HFpred - Predictive model for early detection of decompensation due to heart failure Others Cardiovascular and circulatory systems Predictive model for early detection of decompensation due to heart failure 2PreV España HFpred - Predictive model for early detection of decompensation due to heart failure
Therapeutic area: Cardiovascular and circulatory systems
Vivia Biotech Personalized Medicine Test in Haematological Malignancies Diagnostic Blood and Lymphatic systems
Cancer
Acute Myeloid Leukaemia 5RTM Europe Personalized Medicine Test in Haematological Malignancies
Therapeutic area: Blood and Lymphatic systems
Cancer
Vivia Biotech Personalized Medicine Test in Haematological Malignancies Biomarkers / Diagnostic Cancer Multiple Myeloma 3CV Europe Personalized Medicine Test in Haematological Malignancies
Therapeutic area: Cancer
Vivia Biotech Personalized Medicine Test in Haematological Malignancies Biomarkers / Diagnostic Blood and Lymphatic systems
Cancer
Acute Lymphocytic Leukaemia 3CV Europe Personalized Medicine Test in Haematological Malignancies
Therapeutic area: Blood and Lymphatic systems
Cancer
Vivia Biotech Personalized Medicine Test in Haematological Malignancies Biomarkers / Diagnostic Blood and Lymphatic systems
Cancer
Chronic Lymphocytic Leukaemia 3CV Europe Personalized Medicine Test in Haematological Malignancies
Therapeutic area: Blood and Lymphatic systems
Cancer